Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Clinuvel Pharmaceuticals (ASX:CUV), a rare disease specialist, is held by Jencay Capital for its unique approved therapy. In March 2026, Jencay described Clinuvel's orphan drug SCENESSE as a unique hormone implant used to treat patients with erythropoietic protoporphyria, a rare genetic disorder that causes severe intolerance to light, noting the therapy's established commercial position in the US and Europe and the company's work to expand into new indications. Clinuvel operates in the Healthcare sector within the Biotechnology industry, and Thesis Tracker has captured 6 comments from 2 fund managers, including Jencay Capital. Founded in 1999 and headquartered in Melbourne, Clinuvel develops and commercialises treatments for rare skin and genetic disorders, led by SCENESSE (afamelanotide), approved for erythropoietic protoporphyria in the US, Europe and Australia, and is investigating its use in vitiligo and other conditions, alongside developing related products and a range of over-the-counter photoprotective skincare lines.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Jencay Capital and Elston Asset Management have invested in Clinuvel Pharmaceuticals Ltd (ASX:CUV).
Jencay highlights SCENESSE's unique position as an approved therapy for a rare disease with limited alternatives, providing a durable revenue base and potential expansion into indications such as vitiligo.
The available commentary does not detail specific risks, though Clinuvel's growth depends on regulatory approval for new indications and on its reliance on a single main product.
Clinuvel Pharmaceuticals Ltd. is a Melbourne-based biopharmaceutical company founded in 1999. The firm specializes in developing innovative treatments for rare skin disorders. Its primary product is SCENESSE, a proprietary photoprotective drug designed to address specific dermatological conditions. Clinuvel focuses on the clinical development and commercialization of pharmaceutical solutions for individuals suffering from light-related skin ailments. As a research-driven enterprise, the company continues to manage its drug pipeline and global distribution from its Australian headquarters.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.